Taiwan FDA registration ab45bd22af97dd23f8fa829ee13d7d20

"Serpso" erythrocyte low osmotic ionic strength addition solution

TW: “塞爾普索”紅血球低滲透離子強度添加液

Taiwan·Risk Class 1·CSL LIMITED·Registered Nov 05, 2010 – Nov 05, 2015Cancelled

Registration details

Analysis ID: ab45bd22af97dd23f8fa829ee13d7d20
Customs Code: DHA04400947405

Company information

Manufacturer: CSL LIMITED
Manufacturer Country: Australia
Authorized Representative: GIRAFFES PHARMACEUTICAL COMPANY LTD.

Product details

Intended Use: Limited to the scope of first-level identification of the Measures for the Administration of Medical Devices (B.).
Product Type (Level 1): B Hematology, pathology, and genetics
Product Type (Level 2): B.9600 Intensive medium for in vitro diagnostics
Import Information: import

Dates and status

Registration Date: Nov 05, 2010
Expiry Date: Nov 05, 2015
Cancellation Date: Apr 25, 2018

Cancellation information

Status: Logged out
Reason: 自行鍵入

About this record

Access comprehensive regulatory information for "Serpso" erythrocyte low osmotic ionic strength addition solution in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number ab45bd22af97dd23f8fa829ee13d7d20 and manufactured by CSL LIMITED. The authorized representative in Taiwan is GIRAFFES PHARMACEUTICAL COMPANY LTD..

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.